DAPTOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C72H101N17O26
Molecular Weight	1620.6706
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O

InChI

InChIKey=DOAKLVKFURWEDJ-QCMAZARJSA-N

InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C72H101N17O26
Molecular Weight	1620.6706
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	4
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021572s033lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugbank.ca/drugs/DB00080

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death. Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci, corynebacteria and stationary-phase Borrelia burgdorferi persisters.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus 67 Target ID: CHEMBL352 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Binding Agent 1064
Staphylococcus 2 Target ID: CHEMBL612624 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20176900	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Complicated skin and skin structure infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8429	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 1.06332481E12
Staphylococcus aureus bloodstream infections 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8429	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 1.06332481E12

C_max

Value	Dose	Analyte	Population
141.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
183.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
57.8 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
93.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
123.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59.1 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
92.3 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:

AUC

Value	Dose	Analyte	Population
1039 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1277 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
494 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
632 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
858 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
499 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
821 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:

T_1/2

Value	Dose	Analyte	Population
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
8.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg/kg single, intravenous Highest studied dose Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	unhealthy, 2 - 6 years n = 6 Health Status: unhealthy Condition: bacterial infection Age Group: 2 - 6 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/
6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	Disc. AE: Creatine kinase increased, Renal impairment... AEs leading to discontinuation/dose reduction: Creatine kinase increased (3 patients) Renal impairment (1 patient) Death (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
6 mg/kg single, intravenous Recommended Dose: 6 mg/kg Route: intravenous Route: single Dose: 6 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	unhealthy, 3–24 Months Health Status: unhealthy Condition: proven/suspected bacterial infection Age Group: 3–24 Months Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Cardiac failure, Hypocalcemia... AEs leading to discontinuation/dose reduction: Cardiac failure (4 patients) Hypocalcemia (grade 4, 1 patient) Acute renal failure (1 patient) Acute liver injury (1 patient) Gastrointestinal bleeding (1 patient) Nausea and vomiting (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Acute renal failure, Respiratory failure... AEs leading to discontinuation/dose reduction: Acute renal failure (1 patient) Respiratory failure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

AEs

AE	Significance	Dose	Population
Renal impairment	1 patient Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Death	18 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Creatine kinase increased	3 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Acute liver injury	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Gastrointestinal bleeding	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Nausea and vomiting	2 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Cardiac failure	4 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Hypocalcemia	grade 4, 1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Respiratory failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852 inducer 97	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882	P-gp 1537	CYP1A2 701 CYP2A6 79 CYP2C19 293 CYP2E1 128

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 739	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 970	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://academic.oup.com/jac/article/70/1/307/2911350	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_Pharmr.pdf#page=9 Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:600103	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:600103
ChemicalBook	CB8855073	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8855073
MolPort	MolPort-003-846-138	https://www.molport.com/shop/molecule-link/MolPort-003-846-138
eMolecules	11312095	https://www.emolecules.com/cgi-bin/more?vid=11312095

PubMed

Title	Date	PubMed
Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.	1989 Aug	2552905
Muscle pain associated with daptomycin.	2004 Nov	15367725
Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.	2005 Jan-Feb	15647736
Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.	2005 Oct	16144879
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.	2006 Aug	16787952
Rhabdomyolysis and acute renal failure in a patient treated with daptomycin.	2006 Mar	16410267
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.	2006 Oct	17005801
Eosinophilic pneumonia induced by daptomycin.	2007 Apr	17207858
Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.	2007 Nov	18158084
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.	2007 Oct	17904948
Daptomycin in the treatment of bacteremia.	2007 Oct	17904947
Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.	2008 May	18349306
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.	2008 Nov	18819981
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.	2009 Apr	19188393
Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.	2010 Dec	21119097
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

4 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min) 6 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min)

Route of Administration: Intravenous

In Vitro Use Guide

In vitro activities of daptomycin was studied against more than 100 strains each of Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. For 392 of 421 strains (93%), daptomycin was inhibitory at <1 g/ml,

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:00:48 UTC 2023` Edited by `admin` on `Sat Dec 16 17:00:48 UTC 2023`
Record UNII	NWQ5N31VKK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DAPTOMYCIN

Official Name

English

DAPTOMYCIN [MI]

Common Name

English

LY-146032

Code

English

CUBICIN

Brand Name

English

CIDECIN

Brand Name

English

DAPTOMYCIN [MART.]

Common Name

English

DAPTOMYCIN [ORANGE BOOK]

Common Name

English

daptomycin [INN]

Common Name

English

DAPZURA RT

Brand Name

English

LY 146032

Code

English

DAPTOMYCIN [USAN]

Common Name

English

DAPTOMYCIN [EMA EPAR]

Common Name

English

LY-164032

Code

English

N-DECANOYL-L-TRYPTOPHYL-L-ASPARAGINYL-L-ASPARTYL-L-THREONYLGLYCYL-L-ORNITHYL-L-ASPARTYL-D-ALANYL-L-ASPARTYLGLYCYL-D-SERYL-THREO-3-METHYL-L-GLUTAMYL-3-ANTHRANILOYL-L-ALANINE E1-LACTONE

Common Name

English

DAPTOMYCIN [JAN]

Common Name

English

Daptomycin [WHO-DD]

Common Name

English

DAPCIN

Brand Name

English

DAPTOMYCIN [VANDF]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175509